Skip to Content
Find More Like This
Return to Search

Anti-tenascin monoclonal antibody therapy for lymphoma

United States Patent Application

20020187100
A1
View the Complete Application at the US Patent & Trademark Office
A method of treating lymphoma in a subject comprises administering to a subject afflicted with lymphoma an antibody that binds to tenascin in a therapeutically effective amount. Preferably the antibody is monoclonal antibody 81C6 or an antibody that binds to the epitope bound by monoclonal antibody 81C6. Preferably the antibody is labeled with or conjugated to a chemotherapeutic agent, particularly a radioisotope such as .sup.131I.
Rizzieri, David (Chapel Hill, NC), Bigner, Darell D. (Mebane, NC), Zalutsky, Michael (Chapel Hill, NC)
10/ 008,062
October 19, 2001
[0002] The present invention was made with Government support under grant number NS 20023-18 from the National Institutes of Health and grant number DE-FG-05-95ER62021 from the Department of Energy. The Government has certain rights to this invention.